Agree that the additional trial sites in Turkey is a positive move.
At $50m EV and a P2B readout late this year, PER does offer great value at these prices.
Questions is what else does management have to keep momentum going?
Monkey tox study is almost expected to be good news.
But to get those 48c oppies in the money, we'll need a nice ramp leading into the P2B results.
.
